Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Mavorixafor: a CXCR4 antagonist for WHIM syndrome.
Journal: Immunopharmacology and immunotoxicology
Published: April 14, 2025
Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 10, 2025
Small molecule and peptide CXCR4 antagonists. A patent review from 2019 to 2024.
Journal: Expert opinion on therapeutic patents
Published: February 10, 2025
Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.
Journal: Clinical and experimental immunology
Published: October 18, 2024
Mavorixafor.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: July 30, 2024
CXCR4 antagonism ameliorates leukocyte abnormalities in a preclinical model of WHIM syndrome.
Journal: Frontiers in immunology
Published: July 22, 2024
Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024.
Journal: Annals of medicine and surgery (2012)
Published: July 04, 2024
Xolremdi (Mavorixafor): a breakthrough in WHIM syndrome treatment - unraveling efficacy and safety in a rare disease frontier.
Journal: Annals of medicine and surgery (2012)
Published: June 01, 2024
The promise of novel treatments for severe chronic neutropenia.
Journal: Expert review of hematology
Published: November 18, 2023
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
Journal: Blood
Published: October 11, 2023
Last Updated: 10/31/2025